MedTrace Logo

Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Participants With Chronic Hepatitis C

NCT02725866 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 216

Last updated 2019-03-15

Study results available
· View outcomes & findings →

Summary

The interferon-free combination regimen of paritaprevir/ritonavir/ombitasvir with or without dasabuvir (ABBVIE REGIMEN) ± ribavirin (RBV) for the treatment of chronic hepatitis C (CHC) has been shown to be safe and effective in randomized controlled clinical trials with strict inclusion and exclusion criteria under well-controlled conditions.

This observational study is the first effectiveness research examining the ABBVIE REGIMEN ± RBV, used according to the local label, under real-world conditions in Greece in a clinical practice patient population.

Conditions

  • Chronic Hepatitis C

Interventions

DRUG

Paritaprevir/ritonavir/ombitasvir

Co-formulated tablet

DRUG

Dasabuvir

Tablet

DRUG

Ribavirin

Tablet

Sponsors & Collaborators

Principal Investigators

  • Georgios Mitas, MS · AbbVie Pharmaceuticals S.A. (Greece)

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-05
Primary Completion
2017-10-31
Completion
2017-10-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02725866 on ClinicalTrials.gov